[Clinical and immunological effects of treatment of rheumatoid arthritis with pyrithioxin (Enerbol Polfa)].
D000328:Adult; D000368:Aged; D000936:Antigen-Antibody Complex / Q000032:analysis; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D055598:Chemical Phenomena; D002621:Chemistry; D003875:Drug Eruptions / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007105:Immune Complex Diseases / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D011725:Pyridines / Q000627:therapeutic use*; D011746:Pyrithioxin / Q000009:adverse effects / Q000627:therapeutic use*
D000936:Antigen-Antibody Complex; D011725:Pyridines; D011746:Pyrithioxin
Kliniczne i immunologiczne efekty leczenia pirytioksyna (enerbol "polfa") chorych na reumatoidalne zapalenie stawów.